RT Journal Article
SR Electronic
T1 Modeling serological testing to inform relaxation of social distancing for COVID-19 control
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.24.20078576
DO 10.1101/2020.04.24.20078576
A1 Kraay, Alicia N.M.
A1 Nelson, Kristin N.
A1 Zhao, Conan Y.
A1 Weitz, Joshua S.
A1 Lopman, Benjamin A.
YR 2020
UL http://medrxiv.org/content/early/2020/05/21/2020.04.24.20078576.abstract
AB The value of serological testing to inform the public health response to the SARS-CoV-2 pandemic is debated. Using a transmission model, we examined how serology can be implemented to allow seropositive individuals to resume more normal levels of social interaction while offsetting the risks. We simulated the use of widespread serological testing with realistic assay characteristics, in which seropositive individuals partially restore their social contacts and act as immunological ‘shields’. If social distancing is relaxed by 50% at the same time that quarterly serological screening is initiated, approximately 120,000 deaths could be averted and a quarter of the US population could be released from social distancing in the first year of the epidemic, compared to a scenario without serological testing. This strategy has the potential to substantially flatten the COVID-19 epidemic curve while also allowing a substantial number of individuals to safely return to social and economic interactions.One Sentence Summary Informing relaxation of social distancing with serological testing can reduce population risk while offsetting some of the severe social and economic costs of a sustained shutdown.Competing Interest StatementThe authors have declared no competing interest.Funding StatementBAL and ANMK were supported by the Vaccine Impact Modeling Consortium; BAL and KNN were supported by NIH/NICHD R01 HD097175; BAL, KNN, and ANMK were supported by NIH/NIGMS R01 GM124280; JSW was supported by Simons Foundation (SCOPE Award ID 329108); JSW and CZ were supported by the Army Research Office (W911NF1910384); JSW was supported by NIH (1R01AI46592-01); JSW was supported by National Science Foundation (1806606 and 1829636).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTransmission model code and incidence data used are available at the links provided https://coronavirus.jhu.edu/map.html https://github.com/lopmanlab/Serological_Shielding https://github.com/nytimes/covid-19-data https://covidtracking.com/api